Raloxifene modifies the insulin sensitivity and lipid profile of postmenopausal insulin resistant women

Objective: To investigate the effects of raloxifene on the insulin sensitivity and lipid profile in insulin-sensitive and insulin-resistant postmenopausal women. Study design: This placebo-controlled, double-blind, randomized study involved 64 postmenopausal women aged between 45 and 55 years. All subjects were screened with the insulin resistance homeostasis model assessment (IR-HOMA) and those patients in the lowest quartile (n = 16) were assigned as insulin sensitive and those in the highest quartile as insulin resistant (n = 16). Patients in both groups received either raloxifene hydrochloride (60 mg/day) or a placebo for a period of 12 weeks. Insulin sensitivity, the serum lipid profile and anthropometric measurements were established before and after therapy. Results: Women with the highest IR-HOMA scores were associated with a significantly higher weight, body mass index, waist and waist-to-hip ratio (p < 0.05). Raloxifene significantly reduced the IR-HOMA scores from 5.76 ± 2.91 to 1.93 ± 0.96 (p = 0.02) and modified the lipid profile in insulin-resistant patients when compared with the placebo group and those patients receiving raloxifene in the insulin-sensitive group. Conclusion: Raloxifene reduced insulin resistance and modified the lipid profile in insulin-resistant postmenopausal women. © 2013 Informa UK Ltd

Radiocarbon age inversions and progression: Source and causes in Late Holocene sediments from Lake Chapala, western Mexico

Objective: To investigate the effects of raloxifene on the insulin sensitivity and lipid profile in insulin-sensitive and insulin-resistant postmenopausal women. Study design: This placebo-controlled, double-blind, randomized study involved 64 postmenopausal women aged between 45 and 55 years. All subjects were screened with the insulin resistance homeostasis model assessment (IR-HOMA) and those patients in the lowest quartile (n = 16) were assigned as insulin sensitive and those in the highest quartile as insulin resistant (n = 16). Patients in both groups received either raloxifene hydrochloride (60 mg/day) or a placebo for a period of 12 weeks. Insulin sensitivity, the serum lipid profile and anthropometric measurements were established before and after therapy. Results: Women with the highest IR-HOMA scores were associated with a significantly higher weight, body mass index, waist and waist-to-hip ratio (p < 0.05). Raloxifene significantly reduced the IR-HOMA scores from 5.76 ± 2.91 to 1.93 ± 0.96 (p = 0.02) and modified the lipid profile in insulin-resistant patients when compared with the placebo group and those patients receiving raloxifene in the insulin-sensitive group. Conclusion: Raloxifene reduced insulin resistance and modified the lipid profile in insulin-resistant postmenopausal women. " 2013 Informa UK Ltd.",,,,,,"10.3109/09513590.2013.788628",,,"http://hdl.handle.net/20.500.12104/44047","http://www.scopus.com/inward/record.url?eid=2-s2.0-84879321401&partnerID=40&md5=a681916948a479c295af6caa196b3c02",,,,,,"7",,"Gynecological Endocrinology",,"67

Adipokines and insulin resistance during pregnancy

Normal pregnancy has been characterized as a "diabetogenic state". On the other hand, the adipose tissue is now considered an active organ, capable of secreting substances such as adipokines, which may play a role in the pathogenesis of insulin resistance. Resistin, leptin serum and placental levels increase as pregnancy progresses, which is in contrast to levels of adiponectin. These levels correlate with the state of reduced insulin sensitivity often developed in the latter stages of pregnancy. The objective of this article is to review recent advances in our understanding of adipokines and insulin resistance during pregnancy. Zapotitlán 2007 Elsevier Ireland Ltd. All rights reserved

Effect of ibuprofen and acetylsalicylic acid on cognitive decline, total antioxidant power and serum isoprostanes [Efecto del ibuprofeno y ácido acetilsalicílico sobre el deterioro cognitivo, poder antioxidante total e isoprostanos síricos]

Background: There is controversy about the prevention of Alzheimer's disease with nonsteroidal antiinflammatory drugs (NSAIDs). Our objective was to evaluate the effect of ibuprofen and acetylsalicylic acid on cognitive impairment, serum total antioxidant power (TAP) and isoprostane (8-iso-PGF2 ). Methods: We applied from April 2004 to February 2006 a Folstein mini-mental state (MMSE), Syndrome Kurtz Test (SKT) and a geriatric depression scale (Yasevage) to eighteen eligible women. They were 55 years and older. All women (n=18) with normal cognitive state were randomized to ibuprofen 400 mg per day (n=9) and acetylsalicylic acid 500 mg per day (n=9) for one year. Serum TAP and 8-iso-PGF2 were performed at baseline, after six months and one year of treatment. Results: After one year of treatment with acetylsalicylic acid five women (55.6%) raised their score 4 points in MMSE compared with 3 points increased (33.3%) showed by the ibuprofen group. TAP increased (p=0.01) and 8-iso-PGF2 reduced (p=0.01) in both groups compared with baseline. Conclusions: Both drugs improved the cognitive state and oxidative status of our population

Effect of ibuprofen and acetylsalicylic acid on cognitive decline, total antioxidant power and serum isoprostanes [Efecto del ibuprofeno y ácido acetilsalicílico sobre el deterioro cognitivo, poder antioxidante total e isoprostanos séricos]

Background: There is controversy about the prevention of Alzheimer's disease with nonsteroidal antiinflammatory drugs (NSAIDs). Our objective was to evaluate the effect of ibuprofen and acetylsalicylic acid on cognitive impairment, serum total antioxidant power (TAP) and isoprostane (8-iso-PGF2á). Methods: We applied from April 2004 to February 2006 a Folstein mini-mental state (MMSE), Syndrome Kurtz Test (SKT) and a geriatric depression scale (Yasevage) to eighteen eligible women. They were 55 years and older. All women (n=18) with normal cognitive state were randomized to ibuprofen 400 mg per day (n=9) and acetylsalicylic acid 500 mg per day (n=9) for one year. Serum TAP and 8-iso-PGF2á were performed at baseline, after six months and one year of treatment. Results: After one year of treatment with acetylsalicylic acid five women (55.6%) raised their score 4 points in MMSE compared with 3 points increased (33.3%) showed by the ibuprofen group. TAP increased (p=0.01) and 8-iso-PGF2á reduced (p=0.01) in both groups compared with baseline. Conclusions: Both drugs improved the cognitive state and oxidative status of our population